trending Market Intelligence /marketintelligence/en/news-insights/trending/f2rNgdT-n66ivX-sS503tA2 content esgSubNav
In This List

Mustang Bio CAR-T therapy passes phase 1 trial

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Mustang Bio CAR-T therapy passes phase 1 trial

Mustang Bio Inc.'s gene therapy MB-102 was found to be safe and well tolerated in a phase 1 study to test treatment of two types of blood cancer.

The chimeric antigen receptor T-cell, or CAR-T, drug was used to treat blastic plasmacytoid dendritic cell neoplasm, or BPCDN, and acute myeloid leukemia, or AML, in two separate arms. One patient being treated for BPCDN achieved a complete response, meaning the cancer was no longer present, for at least six months. This was the first-ever reported complete response for the rare blood disease, the company said in the news release.

Patients in both groups received one dose of MB-102, with seven of the 14 patients enrolled treated to date, according to the findings presented at the American Society of Hematology meeting in Atlanta.

BPCDN is a rare and incurable blood cancer with a median survival of less than 18 months. AML is a cancer characterized by rapid growth of abnormal white blood cells.

Mustang Bio is a subsidiary of Fortress Biotech Inc.